Related Experiment Video
Updated: Jun 7, 2026
Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia
Published on: January 6, 2018
Celastrol Activates SIRT1/PGC-1α/Nrf2 Axis to Inhibit Oxidative Damage for Subconjunctival Fibrosis Alleviation
Zhihua Guo1, Huayang Feng1, Xue Sun1
1Henan Eye Hospital, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, PR China.
Purpose:
Subconjunctival fibrosis can lead to symblepharon and recurrent pterygium, seriously threatening vision. Our previous research found that celastrol could inhibit subconjunctival fibrosis. The purpose of this study was to investigate the underlying mechanisms of celastrol-nanomicelles (Cel) in inhibiting subconjunctival fibrosis.
Methods:
We established rat subconjunctival injury model in vivo and TGF-β1-activated human pterygium fibroblasts systems in vitro to study fibrotic pathogenesis. RNA-seq analysis was used to identify the targets of Cel. Immunofluorescence and Western blot analyses were performed to determine whether Cel modulates the SIRT1/PGC-1α/Nrf2 axis, thereby alleviating oxidative damage and subconjunctival fibrosis in vitro. The critical involvement of the SIRT1/PGC-1α/Nrf2 axis was definitively established through pharmacological inhibition using EX527, a selective SIRT1 antagonist. Moreover, the effects of Cel on subconjunctival fibrosis in vivo were further explored through histopathological assessments, Masson's trichrome staining, and immunofluorescence.
Results:
In vivo evaluation with a rat subconjunctival injury model showed that Cel effectively attenuated oxidative damage and subconjunctival fibrosis. The RNA-seq analysis indicated that SIRT1 signal and oxidative stress regulation as candidate targets of Cel for subconjunctival fibrosis. The results of immunofluorescence and Western blot showed that Cel inhibited subconjunctival fibrosis by activating SIRT1/PGC-1α/Nrf2 axis and suppressing TGF-β1/Smad2/3 pathway, while the SIRT1 inhibitor eliminated the effects of Cel.
Conclusions:
This work demonstrated that Cel effectively alleviated subconjunctival fibrosis by inhibiting oxidative damage via activating SIRT1/PGC-1α/Nrf2 signaling pathway, providing a new potential mechanism to clarify Cel as a potential therapeutic drug to inhibit subconjunctival fibrosis.
Insights
Cel-nanomicelles (Cel) inhibit subconjunctival fibrosis by activating the SIRT1/PGC-1α/Nrf2 pathway, reducing oxidative damage. This research clarifies Cel
Area of Science:
- Ophthalmology
- Cell Biology
- Pharmacology
Background:
- Subconjunctival fibrosis, leading to symblepharon and recurrent pterygium, poses a significant threat to vision.
- Previous research identified celastrol as a potential inhibitor of subconjunctival fibrosis.
Purpose of the Study:
- To investigate the mechanisms by which celastrol-nanomicelles (Cel) inhibit subconjunctival fibrosis.
- To explore the role of the SIRT1/PGC-1α/Nrf2 axis in Cel's antifibrotic effects.
Main Methods:
- Established rat subconjunctival injury and human pterygium fibroblast models.
- Utilized RNA-seq, immunofluorescence, and Western blot to analyze Cel's targets and pathways.
- Confirmed the involvement of the SIRT1/PGC-1α/Nrf2 axis using a selective SIRT1 antagonist (EX527).
Main Results:
- Cel effectively attenuated oxidative damage and subconjunctival fibrosis in vivo and in vitro.
- RNA-seq identified SIRT1 signaling and oxidative stress regulation as key targets of Cel.
- Cel inhibited fibrosis by activating the SIRT1/PGC-1α/Nrf2 axis and suppressing the TGF-β1/Smad2/3 pathway.
Conclusions:
- Cel alleviates subconjunctival fibrosis by inhibiting oxidative damage through activation of the SIRT1/PGC-1α/Nrf2 signaling pathway.
- This study provides a novel mechanism for celastrol as a potential therapeutic agent for subconjunctival fibrosis.
